IBI315

DRUG2 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Henan Cancer Hospital

Conditions

Advanced Solid TumorGastric CancerGastroesophageal-junction Cancer

Phase 1

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

CompletedNCT04162327

Innovent Biologics (Suzhou) Co. Ltd.Advanced Solid Tumor

Start: 2019-11-26End: 2023-06-20Updated: 2023-10-24

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Henan Cancer HospitalGastric Cancer, Gastroesophageal-junction Cancer

Start: 2023-01-01End: 2024-10-01Target: 45Updated: 2022-11-08